ARMP Key Statistics, Chart & Performance
The current stock price of ARMP is 6.7 USD. In the past month the price increased by 6.69%. In the past year, price increased by 235%.
ARMP Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ARMP. When comparing the yearly performance of all stocks, ARMP is one of the better performing stocks in the market, outperforming 98.35% of all stocks.
ARMP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ARMP. ARMP has a bad profitability rating. Also its financial health evaluation is rather negative.
ARMP Financial Highlights
Over the last trailing twelve months ARMP reported a non-GAAP Earnings per Share(EPS) of -1.32. The EPS decreased by -15.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ARMP Forecast & Estimates
7 analysts have analysed ARMP and the average price target is 12.24 USD. This implies a price increase of 82.69% is expected in the next year compared to the current price of 6.7.
For the next year, analysts expect an EPS growth of -220.71% and a revenue growth -3.64% for ARMP
ARMP Ownership
About ARMP
Company Profile
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 60 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Company Info
ARMATA PHARMACEUTICALS INC
5005 Mcconnell Ave
Los Angeles CALIFORNIA 90292 US
CEO: Todd R. Patrick
Employees: 60
Phone: 13106652928
ARMATA PHARMACEUTICALS INC / ARMP FAQ
What does ARMATA PHARMACEUTICALS INC do?
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 60 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
What is the current price of ARMP stock?
The current stock price of ARMP is 6.7 USD. The price increased by 0.9% in the last trading session.
Does ARMATA PHARMACEUTICALS INC pay dividends?
ARMP does not pay a dividend.
What is the ChartMill technical and fundamental rating of ARMP stock?
ARMP has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists ARMP stock?
ARMP stock is listed on the NYSE Arca exchange.
What is the Price/Earnings (PE) ratio of ARMATA PHARMACEUTICALS INC (ARMP)?
ARMATA PHARMACEUTICALS INC (ARMP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.32).